Oyster Point Pharma Inc logo

OYST - Oyster Point Pharma Inc News Story

$17.38 0.6  3.3%

Last Trade - 6:42pm

Small Cap
Market Cap £309.4m
Enterprise Value £173.1m
Revenue £n/a
Position in Universe 3674th / 6853

Oyster Point Pharma Announces New Appointment to Board of Directors

Mon 5th April, 2021 11:00am
For best results when printing this announcement, please click on link below:

PRINCETON, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc.
(Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of first-in-class pharmaceutical
therapies to treat ocular surface diseases, today announced the appointment of
an additional member to its Board of Directors.

Effective immediately, George Eliades, Ph.D, current Senior Vice President,
Corporate Development and Chief Transformation Officer of Jazz Pharmaceuticals
(Nasdaq: JAZZ), will join Oyster Point’s Board of Directors and serve as a
member of the Compensation Committee.

“We are excited to welcome George to our Board of Directors as we build the
commercial infrastructure of Oyster Point Pharma,” said President and CEO
Jeffrey Nau, Ph.D., M.M.S. “George has extensive experience developing
global sales and marketing strategies for numerous therapies in biotech and
pharma, and we look forward to his insights and contributions as we work to
bring transformative therapies to patients with ocular surface diseases.”

“I look forward to helping Oyster Point Pharma transform from a development
company to a high growth commercial organization that has the potential to
address unmet needs in the ocular surface disease area for both patients and
eye care professionals,” said Dr. Eliades. “I look forward to being part
of Oyster Point Pharma’s growth as the company prepares for the potential
launch of OC-01 nasal spray and working closely with Jeff and the rest of the

About George Eliades
George Eliades has served as Senior Vice President, Corporate Development and
Chief Transformation Officer of Jazz Pharmaceuticals, a global
biopharmaceutical company, since December 2020. From November 2007 to December
2020, Dr. Eliades was a partner at Bain & Company, where he focused primarily
on advising biopharmaceutical clients. Dr. Eliades has advised multiple
clients on their transformation agendas, including strategy, cost, M&A and
digital driven transformation.

About Oyster Point Pharma
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of first-in-class
pharmaceutical therapies to treat ocular surface diseases. Oyster Point
Pharma’s lead product candidate, OC-01 (varenicline) nasal spray, a highly
selective cholinergic agonist, is being developed as a nasal spray to treat
the signs and symptoms of dry eye disease. In pre-clinical and clinical
studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism
of action via activation of the trigeminal parasympathetic pathway to
stimulate the glands and cells responsible for natural tear film production,
known as the lacrimal functional unit. OC-01 (varenicline) nasal spray is an
investigational new drug and has not been approved for any use in any country.
The safety and efficacy of OC-01 (varenicline) nasal spray have not previously
been established.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995. Forward-looking
statements are neither historical facts nor assurances of future performance.
Instead, they are based on our current beliefs, expectations and assumptions
and on information currently available to us. The forward-looking statements
in this press release represent our views as of the date of this press
release. These statements may include but are not limited to express or
implied statements regarding potential marketing approvals for OC-01 or
regarding other future events, including future development and
commercialization plans. Although we believe the expectations reflected in
such forward-looking statements are reasonable, we can give no assurance that
such expectations will prove to be correct. Forward-looking statements may
involve known and unknown risks, uncertainties and other factors that may
cause our actual results, performance or achievements to be materially
different from those expressed or implied by the forward-looking statements.
Accordingly, readers are cautioned not to place undue reliance on these
forward-looking statements. Except as required by applicable law, we do not
plan to publicly update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events, changed
circumstances or otherwise. No representations or warranties (expressed or
implied) are made about the accuracy of any such forward-looking statements.
Important factors that could cause our actual results to differ materially
include our ability to obtain and maintain regulatory approvals of our product
candidates; our plans relating to commercializing our product candidates, if
approved, including the geographic areas of focus and sales strategy; the
success of competing therapies that are or may become available; the
beneficial characteristics, safety, efficacy and therapeutic effects of our
product candidates, and other factors as detailed from time to time in the
“Risk Factors” section in reports we file with the Securities and Exchange
Commission, copies of which are posted on our website and are available from
us without charge. However, new risk factors and uncertainties may emerge from
time to time, and it is not possible to predict all risk factors and

Investor Contact: 
Tim McCarthy 
LifeSci Advisors, LLC 
(212) 915-2564 

Media Contact: 
Sheryl Seapy, W2O Group
(213) 262-9390


GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.